{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:40:17Z","timestamp":1792708817648,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003000","name":"Stichting MS Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejpn.2020.10.007","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T22:27:20Z","timestamp":1604442440000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["E.U. paediatric MOG consortium consensus: Part 4 \u2013 Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7990-5894","authenticated-orcid":false,"given":"Arlette L.","family":"Bruijstens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Breu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Wendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Wassmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6136-4981","authenticated-orcid":false,"given":"Rinze F.","family":"Neuteboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Wickstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.U. paediatric","family":"Mog consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlette L.","family":"Bruijstens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Wendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Breu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Flet-Berliac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali\u00e9nor","family":"de Chalus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgi","family":"Laetitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Hemingway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Wassmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Wickstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00eds","family":"Armangue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaran","family":"Deiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinze F.","family":"Neuteboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejpn.2020.10.007_bib1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1471-4159.1989.tb10930.x","article-title":"Differential ultrastructural localization of myelin basic protein, myelin\/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats","volume":"52","author":"Brunner","year":"1989","journal-title":"J.\u00a0Neurochem."},{"issue":"2","key":"10.1016\/j.ejpn.2020.10.007_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.007_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0037-1604404","article-title":"MOG spectrum disorders and role of MOG-antibodies in clinical practice","volume":"49","author":"Hennes","year":"2018","journal-title":"Neuropediatrics"},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.007_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpn.2020.10.007_bib5","doi-asserted-by":"crossref","unstructured":"Arlette L. Bruijstens, et\u00a0al., E.U. paediatric MOG consortium consensus: Part 1 \u2013 Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur. J. Paediatr. Neurol. 2020, https:\/\/doi.org\/10.1016\/j.ejpn.2020.10.006.","DOI":"10.1016\/j.ejpn.2020.10.006"},{"issue":"12","key":"10.1016\/j.ejpn.2020.10.007_bib6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1177\/1352458514566666","article-title":"Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort","volume":"21","author":"Ketelslegers","year":"2015","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.ejpn.2020.10.007_bib7","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1212\/NXI.0000000000000081","article-title":"Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children","volume":"2","author":"Hacohen","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflam."},{"key":"10.1016\/j.ejpn.2020.10.007_bib8","doi-asserted-by":"crossref","unstructured":"Arlette L. Bruijstens, et\u00a0al., E.U. paediatric MOG consortium consensus: Part 5 \u2013 Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur. J. Paediatr. Neurol. 2020, https:\/\/doi.org\/10.1016\/j.ejpn.2020.10.005.","DOI":"10.1016\/j.ejpn.2020.10.006"},{"key":"10.1016\/j.ejpn.2020.10.007_bib9","doi-asserted-by":"crossref","unstructured":"Matthias Baumann, et\u00a0al., E.U. paediatric MOG consortium consensus: Part 2 - Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur. J. Paediatr. Neurol. 2020, https:\/\/doi.org\/10.1016\/j.ejpn.2020.10.002","DOI":"10.1016\/j.ejpn.2020.10.002"},{"key":"10.1016\/j.ejpn.2020.10.007_bib10","doi-asserted-by":"crossref","unstructured":"Tha\u00eds Armangue, et\u00a0al., E.U. paediatric MOG consortium consensus: Part 3 \u2013 Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur. J. Paediatr. Neurol. 2020, https:\/\/doi.org\/10.1016\/j.ejpn.2020.11.001.","DOI":"10.1016\/j.ejpn.2020.11.001"},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.007_bib11","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.007_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","article-title":"Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein","volume":"86","author":"Baumann","year":"2015","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatr."},{"issue":"8","key":"10.1016\/j.ejpn.2020.10.007_bib13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp-2015-311743","article-title":"Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease","volume":"87","author":"Lechner","year":"2016","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"11","key":"10.1016\/j.ejpn.2020.10.007_bib14","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejpn.2020.10.007_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2018.03.003","article-title":"Clinical characteristics of pediatric optic neuritis with myelin oligodendrocyte glycoprotein seropositive: a cohort study","volume":"83","author":"Chen","year":"2018","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ejpn.2020.10.007_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.msard.2018.11.026","article-title":"Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients","volume":"28","author":"Narayan","year":"2019","journal-title":"Mult Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.ejpn.2020.10.007_bib17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/bjophthalmol-2018-312399","article-title":"Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China","volume":"103","author":"Song","year":"2019","journal-title":"Br. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.ejpn.2020.10.007_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaneurol.2014.3602","article-title":"Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor alpha1 subunit in patients with isolated optic neuritis","volume":"72","author":"Martinez-Hernandez","year":"2015","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.ejpn.2020.10.007_bib19","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/mp.2014.25","article-title":"Antibodies to NMDA receptor, blood-brain barrier disruption and schizophrenia: a theory with unproven links","volume":"19","author":"Titulaer","year":"2014","journal-title":"Mol. Psychiatr."},{"issue":"12","key":"10.1016\/j.ejpn.2020.10.007_bib20","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.ejpn.2020.10.007_bib21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejpn.2020.10.007_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2018.07.022","article-title":"Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders","volume":"26","author":"Konuskan","year":"2018","journal-title":"Mult Scler. Relat. Disord."},{"key":"10.1016\/j.ejpn.2020.10.007_bib23","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fneur.2019.00868","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody diseases in children in central south China: clinical features, treatments, influencing factors, and outcomes","volume":"10","author":"Mao","year":"2019","journal-title":"Front. Neurol."},{"issue":"9","key":"10.1016\/j.ejpn.2020.10.007_bib24","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2020.10.007_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.msard.2018.12.001","article-title":"Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination","volume":"28","author":"Zhou","year":"2019","journal-title":"Mult Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.ejpn.2020.10.007_bib26","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1177\/1352458517706038","article-title":"Fatigue and physical functioning in children with multiple sclerosis and acute disseminated encephalomyelitis","volume":"24","author":"Toussaint-Duyster","year":"2018","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.007_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ejpn.2020.10.007_bib28","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","author":"de Mol","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejpn.2020.10.007_bib29","first-page":"4015075","article-title":"Different characteristics of aquaporin-4 and myelin oligodendrocyte glycoprotein antibody-seropositive male optic neuritis in China","volume":"2019","author":"Song","year":"2019","journal-title":"J.\u00a0Ophthalmol."},{"issue":"12","key":"10.1016\/j.ejpn.2020.10.007_bib30","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/dmcn.13757","article-title":"Retinal nerve fibre layer thinning is associated with worse visual outcome after optic neuritis in children with a relapsing demyelinating syndrome","volume":"60","author":"Eyre","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ejpn.2020.10.007_bib31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejpn.2020.04.002","article-title":"High association of MOG-IgG antibodies in children with bilateral optic neuritis","volume":"27","author":"Wendel","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"10","key":"10.1016\/j.ejpn.2020.10.007_bib32","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis","volume":"125","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.007_bib33","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.007_bib34","article-title":"MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response","volume":"4","author":"Pandit","year":"2018","journal-title":"Multi. Scler. J. Exp. Transl. Clinic."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.007_bib35","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J.\u00a0Neuroinflammation"},{"issue":"7","key":"10.1016\/j.ejpn.2020.10.007_bib36","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/1352458512466317","article-title":"Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients","volume":"19","author":"Huppke","year":"2013","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.ejpn.2020.10.007_bib37","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/ene.13602","article-title":"Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome","volume":"25","author":"Wong","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.ejpn.2020.10.007_bib38","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.20851","article-title":"Quantifying axonal loss after optic neuritis with optical coherence tomography","volume":"59","author":"Costello","year":"2006","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.007_bib39","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12974-019-1521-5","article-title":"Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study","volume":"16","author":"Oertel","year":"2019","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ejpn.2020.10.007_bib40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jneuroim.2018.09.011","article-title":"Retinal nerve fiber layer thickness in optic neuritis with MOG antibodies: a systematic review and meta-analysis","volume":"325","author":"Peng","year":"2018","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.ejpn.2020.10.007_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2018.05.014","article-title":"Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: a multicenter study in South China","volume":"321","author":"Chen","year":"2018","journal-title":"J.\u00a0Neuroimmunol."},{"issue":"21","key":"10.1016\/j.ejpn.2020.10.007_bib42","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.007_bib43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.007_bib44","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J.\u00a0Neuroinflammation"},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.007_bib45","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ene.12898","article-title":"Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in The Netherlands","volume":"23","author":"van Pelt","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.ejpn.2020.10.007_bib46","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12732","article-title":"Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease","volume":"2","author":"Mariano","year":"2019","journal-title":"Jama Netw Open"},{"issue":"7","key":"10.1016\/j.ejpn.2020.10.007_bib47","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"Hoftberger","year":"2015","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.007_bib48","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.ejpn.2020.10.007_bib49","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/dmcn.13703","article-title":"Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes","volume":"60","author":"Duignan","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"issue":"14","key":"10.1016\/j.ejpn.2020.10.007_bib50","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1177\/1352458516631038","article-title":"Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases","volume":"22","author":"Baumann","year":"2016","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.ejpn.2020.10.007_bib51","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dmcn.14594","article-title":"Risk factors for academic difficulties in children with myelin oligodendrocyte glycoprotein antibody-associated acute demyelinating syndromes","volume":"62","author":"Deiva","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"issue":"9","key":"10.1016\/j.ejpn.2020.10.007_bib52","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/ene.13102","article-title":"Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study","volume":"23","author":"Nourbakhsh","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"16 Suppl 2","key":"10.1016\/j.ejpn.2020.10.007_bib53","first-page":"S66","article-title":"The psychosocial consequences of pediatric multiple sclerosis","volume":"68","author":"MacAllister","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.007_bib54","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/1352458518823486","article-title":"Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis","volume":"26","author":"Rossor","year":"2020","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.ejpn.2020.10.007_bib55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2019","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2020.10.007_bib56","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","article-title":"Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases","volume":"138","author":"Di Pauli","year":"2011","journal-title":"Clin. Immunol."},{"issue":"6","key":"10.1016\/j.ejpn.2020.10.007_bib57","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis","volume":"77","author":"Probstel","year":"2011","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ejpn.2020.10.007_bib58","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1177\/1352458512470310","article-title":"Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica","volume":"19","author":"Rostasy","year":"2013","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.ejpn.2020.10.007_bib59","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflam."},{"issue":"6","key":"10.1016\/j.ejpn.2020.10.007_bib60","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/archneurol.2011.2956","article-title":"Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis","volume":"69","author":"Rostasy","year":"2012","journal-title":"Arch. Neurol."},{"issue":"11","key":"10.1016\/j.ejpn.2020.10.007_bib61","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1177\/1352458515618541","article-title":"Neurogenic lower urinary tract dysfunction in the early disease phase of paediatric multiple sclerosis","volume":"22","author":"Scheepe","year":"2016","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.ejpn.2020.10.007_bib62","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1212\/WNL.0b013e318288694e","article-title":"International pediatric MS study group clinical trials summit: meeting report","volume":"80","author":"Chitnis","year":"2013","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ejpn.2020.10.007_bib63","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ejpn.2019.08.006","article-title":"The Multiple Sclerosis Inventory of Cognition for Adolescents (MUSICADO): a brief screening instrument to assess cognitive dysfunction, fatigue and loss of health-related quality of life in pediatric-onset multiple sclerosis","volume":"23","author":"Storm Van's Gravesande","year":"2019","journal-title":"Eur. J. Paediatr. Neurol. : EJPN : Off. J. Eur. Paediatr. Neurol. Soc."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379820302002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379820302002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:38:17Z","timestamp":1761071897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379820302002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":63,"alternative-id":["S1090379820302002"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2020.10.007","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"E.U. paediatric MOG consortium consensus: Part 4 \u2013 Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2020.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}